CXCL8 and cancer: For instance, CXCL8-induced NETs have been preliminarily shown to contribute to cancer development and progression; furthermore, blockade of CXCL8 or its receptors (CXCR1 and CXCR2) is being pursued for drug development, and clinical trials of such drugs used alone or in combination with anti-PD-L1 checkpoint inhibitors are already ongoing [271].